AbbVie to ring in 2013 as an independent drugmaker

AbbVie has its final stamp of approval. Abbott Laboratories' ($ABT) directors endorsed the pharma unit's spinoff Wednesday, allowing AbbVie to ring in the new year as an independent company.Abbott shareholders will receive one share of AbbVie's common stock for each Abbott share they own. AbbVie's shares will hit New Year's Day, with trading expected to begin on the New York Stock Exchange when markets reopen Jan. 2. Ticker symbol: ABBV. Story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.